NCT03535870View on ClinicalTrials.gov

Clinical Endpoint Bioequivalence Study of Fluticasone Propionate & Salmeterol Xinafoate (100μg/50μg)

NACompletedINTERVENTIONAL
Enrollment

1,556

Participants

Timeline

Start Date

April 26, 2018

Primary Completion Date

September 10, 2019

Study Completion Date

September 10, 2019

Conditions
Asthma
Interventions
DRUG

Fluticasone propionate/salmeterol

Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the LOMI inhaler device

DRUG

Advair Diskus, 100 Mcg-50 Mcg Inhalation Powder

Advair (Fixed dose combination of fluticasone propionate and salmeterol xinafoate administered via the Diskus inhaler device)

DRUG

Placebo

placebo dry powder administered via the LOMI inhaler device

Trial Locations (1)

89119

West-Ward Research Site #1, Las Vegas

All Listed Sponsors
lead

West-Ward Pharmaceutical

INDUSTRY

NCT03535870 - Clinical Endpoint Bioequivalence Study of Fluticasone Propionate & Salmeterol Xinafoate (100μg/50μg) | Biotech Hunter | Biotech Hunter